CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource, 1 online resource.

Language: Englisch

Bibliographic citation: CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis ; volume:23 ; number:1 ; day:29 ; month:8 ; year:2023 ; pages:1-11 ; date:12.2023
BMC cancer ; 23, Heft 1 (29.8.2023), 1-11, 12.2023

Creator: Ji, Danyang
Luo, Yang
Wang, Jiayu
Chen, Shanshan
Lan, Bo
Ma, Fei
Xu, Binghe
Fan, Ying

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-023-11290-7

URN: urn:nbn:de:101:1-2023110711454311409095

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ji, Danyang
Luo, Yang
Wang, Jiayu
Chen, Shanshan
Lan, Bo
Ma, Fei
Xu, Binghe
Fan, Ying
SpringerLink (Online service)

Other Objects (12)

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Development of dual BET/HDAC inhibitors

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer

CIK Cells and HDAC Inhibitors in Multiple Myeloma

HDAC inhibitors stimulate viral transcription by multiple mechanisms

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Development of dual BET/HDAC inhibitors

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer

CIK Cells and HDAC Inhibitors in Multiple Myeloma

HDAC inhibitors stimulate viral transcription by multiple mechanisms

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Development of dual BET/HDAC inhibitors

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer

CIK Cells and HDAC Inhibitors in Multiple Myeloma

HDAC inhibitors stimulate viral transcription by multiple mechanisms

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Development of dual BET/HDAC inhibitors

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer

CIK Cells and HDAC Inhibitors in Multiple Myeloma

HDAC inhibitors stimulate viral transcription by multiple mechanisms

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Development of dual BET/HDAC inhibitors

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer

CIK Cells and HDAC Inhibitors in Multiple Myeloma

HDAC inhibitors stimulate viral transcription by multiple mechanisms

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Development of dual BET/HDAC inhibitors

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer

CIK Cells and HDAC Inhibitors in Multiple Myeloma

HDAC inhibitors stimulate viral transcription by multiple mechanisms

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Related objects

Reset password